"In response to the opinions of medical institutions and relevant enterprises who want to speed up the admission of new technologies, new equipment and new consumables, the National Medical Insurance Bureau guides provinces to further open new channels for medical service price projects, and open green channels for major innovative projects that optimize the diagnosis and treatment plans for major diseases or fill the diagnosis and treatment gaps." On September 10, Yan Qinghui, deputy director of the National Healthcare Security Administration, said at the press conference on the theme of "Promoting high-quality development" of The State Council.

According to reports, for the improved innovation project, the National Medical Insurance Bureau will also improve the current price project, achieve compatibility, and quickly meet reasonable charging needs; For other new price items, accelerate the acceptance and review progress, and fully meet the reasonable charging needs of new technologies, new equipment, and new consumables at different levels of innovation.

We will accelerate the acceptance of applications for new projects such as innovative medical devices

Yan Qinghui introduced that the National Medical Insurance Bureau has always clearly supported medical technology innovation, and promoted the high-quality development of medical services by improving the price policy of medical services. The National Medical Insurance Bureau organized experts to speed up the preparation of national medical service price project specifications, in accordance with the principle of mature batch release batch, has issued nine batch project guidelines such as obstetrics, nursing, unified standardization of medical service price projects in related disciplines, highlighting the medical service as the leading.

Since 2022, provinces across the country have added more than 1,000 price projects every year, and a number of high-quality innovative technologies, equipment and consumables have entered clinical application, so that innovative medical technologies can better benefit the people.

In the next step, the National Medical Insurance Bureau will earnestly implement the spirit of the Third Plenary Session of the 20th Central Committee of the Party, accelerate the preparation of medical service price project specifications, continue to guide provincial medical insurance bureaus to optimize the management of new projects based on clinical value and innovation quality, and accelerate the acceptance of new projects of major innovative technologies such as medical devices that are reviewed and approved by the National Food and Drug Administration. Promote the development of new quality productivity in the medical field.

Yan Qinghui stressed that the National Medical Insurance Bureau will also strengthen the quality control of innovation to prevent low-quality fake innovation from disrupting the market environment and crowding out the medical insurance fund. We also hope that relevant enterprises can effectively improve the quality of innovation, do a good job of disclosing the price of high-value medical consumables involved in new price projects, and accept social supervision and peer review.

Cochlear implants will be included in the fifth batch of consumables

"The collection of new batches of state-organized drugs and high-value medical consumables will include high-value medical consumables such as cochlear implants in the collection range." Yan Qinghui said.

Data show that the current network price of cochlear implants ranges from 80,000 yuan to 270,000 yuan, in addition, patients also need to pay for surgery and later maintenance costs, and the overall treatment cost is more expensive.

The reporter noted that the news released by the National Medical Insurance Bureau official micro blog during the Children's Day this year shows that as of the first half of the year, Xinjiang, Jilin, Shanghai, Jiangsu, Zhejiang, Anhui, Fujian, Jiangxi, Shandong, Henan, Guangdong, Guangxi, Hainan and other provinces have included cochlear implants in the local medical insurance reimbursement scope, the highest payment standard can reach 450,000 yuan.

With the help of medical insurance payments and financial subsidies, the number of domestic cochlear implant operations has continued to grow in recent years, and the market size of cochlear implants has grown rapidly. According to data from Mass Data, the market size of cochlear implants has grown from 350 million yuan in 2019 to 744 million yuan in 2023, with a compound annual growth rate of 20.72%. The market size is expected to reach 976 million in 2024, with a growth rate of 31.16%.

In recent years, the State Medical Insurance Bureau institutionalized and normalized drug consumables collection, the state has organized 9 batches of drug collection and 4 batches of high-value medical consumables collection, while guiding and promoting local collection for varieties other than national collection.

According to reports, the National Medical Insurance Bureau to centralized procurement as the driving force, to achieve a deeper level, higher quality "cage change bird." The cost space freed up by centralized procurement first releases reform dividends to the people, at the same time makes room for promoting new drugs and new diagnosis and treatment projects that reflect new quality productivity to enter clinical application, and also creates conditions for the adjustment of medical service prices. Since 2021, the National Medical Insurance Administration has guided provinces across the country to dynamically adjust medical service prices, carry out pilot medical service price reform, and explore the establishment of a new medical service price formation mechanism that ADAPTS to economic and social development, better plays the role of the government, fully participates in medical institutions, and reasonably reflects the value of technical labor. Since the reform, the prices of technical items such as surgery and traditional Chinese medicine have been raised in an orderly manner, and the prices of inspection and inspection items such as CT have been lowered reasonably, and the pace of price adjustment has matched the development of economy and society.

It is reported that in the next step, the medical insurance department will vigorously promote the quality of pharmaceutical collection and expansion. Strengthen regional coordination, and focus on guiding local governments to promote the alliance collection of pharmaceutical consumables such as proprietary Chinese medicines, Chinese herbal decoction pieces, and in vitro diagnostic reagents. Steadily promote the continuation of procurement, strengthen the refined management of collection and execution, strengthen the management measures of the use, supply and monitoring of selected products in conjunction with relevant departments, urge the selected products to enter the hospital in time and give priority to use, and take measures to consolidate the selected enterprises to ensure quality and supply responsibility.